Session 12 – Asian Opportunities & Collaborations
Date: 24 July (Friday) 12:20 – 13:50 (GMT+8)
Venue: 701EF, 7F, TaiNEX2 / Online event platform
Most recently, Prof Damian O’Connell was Senior Vice President, Drug Discovery – Global Head of Clinical Sciences, Bayer Pharma AG, Berlin – Germany. Clinical Sciences (CS) is a global
function within Bayer (based in Germany, US, Japan, China) with responsibility for the first use of drug products in humans up to Proof of Concept, as well as all clinical pharmacological
components of NDAs.
Prof O’Connell previously held senior positions within Pfizer Research & Development, Parke Davis, Elan Pharmaceuticals and Neurex. Prof O’Connell has both MD & PhD degrees from the
National University of Ireland, has been a Medical Faculty member of the University of Virginia Health Sciences Center as well as a member of the Clinical Pharmacology & Therapeutics
Department at the University College Cork, Ireland where he was a Professor of Clinical Research. He started his career in the Industry in 1998.
Prof O’Connell is a Member of the Faculty of Pharmaceutical Medicine; Fellow of The Royal Society of Medicine; Fellow of The Royal Academy of Medicine (Ireland); Member of the British
Pharmacological Society; Member of the Drug Safety Executive Council (DSEC); Member American Society for Clinical Pharmacology and Therapeutics; Member American College of
Clinical Pharmacology; Member of American Society of Pharmacometrics; Member of the Irish Association of Pharmacologists; Member of the Irish Cardiac Society; and Member of the British Hypertension Society.
Speech title & Synopsis
When the Singapore ecosystem was developed 20 years ago, pharmaceutical companies were tapped as the innovation engine. As a result, the ecosystem was modelled to welcome and support large pharma research and development. However, the drug development value chain has evolved over the past two decades with a shift in roles between pharmaceutical companies, biotech companies, and venture capital firms. In order to be successful, Singapore has to build upon the investments in health and biomedical sciences in the past 20 years, and its reputation in research and innovation; and make a concerted effort to drive tangible outcomes in translational research and commercial outcomes. A*STAR Experimental Drug Development Centre (EDDC) plays a critical role in this aspect.
EDDC is Singapore’s national centre for drug discovery and development. It is integrated from three former drug units – Experimental Therapeutics Centre (ETC), Drug, Discovery and Development (D3), and Experimental Biotherapeutics Centre (EBC). Together, these three units have forged partnerships with more than 70 academic institutions and 25 companies, locally and internationally, with 20 licensing deals executed. EDDC officially opened in June 2019 and has a full range of drug discovery capabilities, from assay development, high throughput screening, antibody cloning, medicinal chemistry, to the design and management of Proof-of-Mechanism or Proof-of-Concept Studies. EDDC aims to develop therapeutics
that save and improve the lives of patients in Asia and around the world, in collaboration with academic and industry partners.